References
Costagliola C, Parmeggiani F, Sebastiani A. SSRIs and intraocular pressure modifications: evidence, therapeutic impli cations and possible mechanisms. CNS Drugs 2004; 18(8): 475–84
Ahmad S. Fluoxetine and glaucoma [letter]. DICP 1991; 25: 436
Kirwan JF, Subak-Sharpe I, Teimory M. Bilateral acute angle closure glaucoma after administration of paroxetine [letter]. Br J Ophthalmol 1997; 81: 252
Lewis CF, DeQuardo JR, DuBose C, et al. Acute angle-closure glaucoma and paroxetine. J Clin Psychiatry 1997; 58: 123–4
Eke T, Bates AK. Acute angle closure glaucoma associated with paroxetine [letter]. BMJ 1997; 314: 1387
Bennett HG, Wyllie AM. Paroxetine and acute angle-closure glaucoma. Eye 1999; 13: 691–2
Browning AC, Reck AC, Chisholm IH, et al. Acute angle closure glaucoma presenting in a young patient after administration of paroxetine. Eye 2000; 14: 406–8
Jimenez-Jimenez FJ, Orti-Pareja M, Zurdo JM. Aggravation of glaucoma with fluvoxamine. Ann Pharmacother 2001; 35: 1565–6
Meyboom RH, Egberts AC, Edwards IR, et al. Principles of signal detection in pharmacovigilance. Drug Saf 1997; 16(6): 355–65
Hauben M. A brief primer on automated signal detection. Ann Pharmacother 2002; 37(7/8): 1117–26
Finney DJ. The detection of adverse reactions to therapeutic drugs. Stat Med 1982; 1(2): 153–61
Acknowledgements
The authors are employees of Pfizer Inc, which manufactures and markets sertraline.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hauben, M., Reich, L. Reports of Acute Angle Closure Glaucoma-Related Adverse Events with SSRIs: Results of a Disproportionality Analysis. CNS Drugs 20, 327–329 (2006). https://doi.org/10.2165/00023210-200620040-00006
Published:
Issue Date:
DOI: https://doi.org/10.2165/00023210-200620040-00006